Dr. Emens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 N Wolfe St
Suite 4628
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 412-623-1212
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2002
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1995 - 1998
- Baylor College of MedicineClass of 1995
Certifications & Licensure
- CA State Medical License 2024 - 2026
- MD State Medical License 1998 - 2026
- PA State Medical License 2018 - 2024
- TX State Medical License 1997 - 1999
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- America's Top Doctors for Cancer Castle Connolly, 2011-2013
- Join now to see all
Clinical Trials
- Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer Start of enrollment: 2004 Jan 01
- Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer Start of enrollment: 2006 Sep 01
- Cytokine Expression During Radiation for Breast Cancer Start of enrollment: 2009 Nov 13
- Join now to see all
Publications & Presentations
PubMed
- 524 citationsLong-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.Leisha A. Emens, Cristina Cruz, Joseph Paul Eder, Fadi Braiteh, Cathie Chung
JAMA Oncology. 2019-01-01 - 89 citationsPD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.Hope S. Rugo, Sherene Loi, Sylvia Adams, Peter Schmid, Andreas Schneeweiss
Journal of the National Cancer Institute. 2021-06-07 - 551 citationsAtezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios
The New England Journal of Medicine. 2018-11-29
Journal Articles
- Association of Cancer Immunotherapy with Acute Macular Neuroretinopathy and Diffuse Retinal VenulitisSharon Solomon, Christopher H Lieu, Ashvini Reddy, Leisha A Emens, S Lindsey Davis, Lingmin He, JAMA
Lectures
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerInternational Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/24/2012
- Breast and Gynecologic Cancers. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1)2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Press Mentions
- Ankyra Therapeutics Appoints Leisha a. Emens, M.D., Ph.D., as Senior Vice President, Translational ResearchDecember 7th, 2022
- Crisis in Oncology Research Demands Urgent Action, Stakeholders SayNovember 4th, 2022
- Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Breast CancerAugust 18th, 2021
- Join now to see all
Grant Support
- Chemoimmunotherapy For Breast Cancer TreatmentNational Cancer Institute2003–2006
Professional Memberships
- Member
- Member
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/leisha-emens
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: